{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:48:54Z","timestamp":1778510934134,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":158,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1002\/rth2.12744","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:31:12Z","timestamp":1656660672000},"page":"e12744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment\u2014A report from ICTHIC 2021"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-3457","authenticated-orcid":false,"given":"Anna","family":"Falanga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-0998","authenticated-orcid":false,"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles\u00a0W.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1002\/rth2.12744_bb0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/M17-0868","article-title":"Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta\u2010analysis of individual patient data","volume":"167","author":"van Es","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1002\/rth2.12744_bb0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1160\/TH16-10-0823","article-title":"Venous thromboembolism: past, present and future","volume":"117","author":"Schulman","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12744_bb0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1160\/TH03-11-0699","article-title":"In proven deep vein thrombosis, a low positive D\u2010Dimer score is a strong negative predictor for associated malignancy","volume":"91","author":"Rege","year":"2004","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12744_bb0025","first-page":"214","article-title":"The predictive value of D\u2010dimer measurement for cancer in patients with deep vein thrombosis","volume":"90","author":"Schutgens","year":"2005","journal-title":"Haematologica"},{"issue":"12 suppl","key":"10.1002\/rth2.12744_bb0030","first-page":"ELT08","article-title":"High D\u2010dimer level at presentation in patients with venous thrombosis is a marker for malignancy","volume":"90","author":"Paneesha","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/rth2.12744_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153514","article-title":"Impact of D\u2010dimer for prediction of incident occult cancer in patients with unprovoked venous thromboembolism","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1002\/rth2.12744_bb0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000484668","article-title":"When to screen ischaemic stroke patients for cancer","volume":"45","author":"Selvik","year":"2018","journal-title":"Cerebrovasc Dis"},{"issue":"2021","key":"10.1002\/rth2.12744_bb0045","doi-asserted-by":"crossref","first-page":"5585206","DOI":"10.1155\/2021\/5585206","article-title":"Score for predicting active cancer in patients with ischemic stroke: a retrospective study","volume":"25","author":"Jiang","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1002\/rth2.12744_bb0050","doi-asserted-by":"crossref","first-page":"100030","DOI":"10.1016\/j.tru.2020.100030","article-title":"Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: rationale and design of the PLATO\u2010VTE study","volume":"2","author":"Kraaijpoel","year":"2021","journal-title":"Thromb Update"},{"issue":"15","key":"10.1002\/rth2.12744_bb0055","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/bloodadvances.2017007955","article-title":"Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis\u2010associated cancer","volume":"1","author":"Mohammed","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1002\/rth2.12744_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003725","article-title":"Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study","volume":"3","author":"Iacoviello","year":"2013","journal-title":"BMJ Open"},{"issue":"4","key":"10.1002\/rth2.12744_bb0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/s-0040-1718531","article-title":"Tissue plasminogen activator levels and risk of breast cancer in a case\u2010cohort study on Italian women: results from the Moli\u2010sani study","volume":"121","author":"Costanzo","year":"2021","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12744_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J","article-title":"Occult cancer in patients with deep venous thrombosis. A systematic approach","volume":"67","author":"Monreal","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/rth2.12744_bb0075","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1378\/chest.103.3.816","article-title":"Occult cancer in patients with acute pulmonary embolism. A prospective study","volume":"103","author":"Monreal","year":"1993","journal-title":"Chest"},{"issue":"8","key":"10.1002\/rth2.12744_bb0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa1506623","article-title":"Screening for occult cancer in unprovoked venous thromboembolism","volume":"373","author":"Carrier","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/rth2.12744_bb0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(15)00480-5","article-title":"Limited screening with versus without (18)F\u2010fluorodeoxyglucose PET\/CT for occult malignancy in unprovoked venous thromboembolism: an open\u2010label randomised controlled trial","volume":"17","author":"Robin","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1002\/rth2.12744_bb0090","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"Dunbar","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1002\/rth2.12744_bb0095","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/bloodadvances.2020002998","article-title":"Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles","volume":"5","author":"Tawil","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"10.1002\/rth2.12744_bb0100","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1002\/rth2.12744_bb0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2017-02-768218","article-title":"Identification of the integrin\u2010binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling","volume":"131","author":"Rothmeier","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1002\/rth2.12744_bb0110","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1073\/pnas.97.10.5255","article-title":"Tissue factor\u2010 and factor X\u2010dependent activation of protease\u2010activated receptor 2 by factor VIIa","volume":"97","author":"Camerer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"10.1002\/rth2.12744_bb0115","doi-asserted-by":"crossref","first-page":"eaaw8405","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cell\u2010synthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1002\/rth2.12744_bb0120","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/rth2.12431","article-title":"Preventing venous thromboembolism in oncology practice: use of risk assessment and anticoagulation prophylaxis","volume":"4","author":"Martin","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12744_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer\u2010associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"23","key":"10.1002\/rth2.12744_bb0130","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer\u2010a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1002\/rth2.12744_bb0135","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer\u2010associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1002\/rth2.12744_bb0140","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"10.1002\/rth2.12744_bb0145","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.2147\/OTT.S103735","article-title":"Risk of venous and arterial thromboembolic events associated with anti\u2010VEGF agents in advanced non\u2010small\u2010cell lung cancer: a meta\u2010analysis and systematic review","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1002\/rth2.12744_bb0150","doi-asserted-by":"crossref","first-page":"F134","DOI":"10.1152\/ajprenal.00405.2018","article-title":"ADAMTS13 protects mice against renal ischemia\u2010reperfusion injury by reducing inflammation and improving endothelial function","volume":"316","author":"Zhou","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"10.1002\/rth2.12744_bb0155","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy\u2010associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1002\/rth2.12744_bb0160","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jth.14824","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta\u2010analysis","volume":"18","author":"van Es","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1002\/rth2.12744_bb0165","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1002\/rth2.12744_bb0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1002\/rth2.12744_bb0175","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ajh.24466","article-title":"Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients","volume":"91","author":"Antic","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1002\/rth2.12744_bb0180","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug\u2010associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1002\/rth2.12744_bb0185","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12744_bb0190","series-title":"Quality in Laboratory Hemostasis and Thrombosis","first-page":"22","author":"Lippi","year":"2013"},{"issue":"4","key":"10.1002\/rth2.12744_bb0195","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1002\/rth2.12744_bb0200","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1002\/rth2.12744_bb0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2016-12-758995","article-title":"Effect of a near\u2010universal hospitalization\u2010based prophylaxis regimen on annual number of venous thromboembolism events in the US","volume":"130","author":"Heit","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1002\/rth2.12744_bb0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1002\/rth2.12744_bb0215","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose\u2010adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double\u2010blinded multicenter phase 2 trial","volume":"4","author":"Zwicker","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1002\/rth2.12744_bb0220","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population\u2010based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1002\/rth2.12744_bb0225","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo\u2010controlled, double\u2010blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1002\/rth2.12744_bb0230","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/rth2.12744_bb0235","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"18","key":"10.1002\/rth2.12744_bb0240","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low\u2010molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO\u2010004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1002\/rth2.12744_bb0245","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1002\/rth2.12744_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and safety of apixaban, low\u2010molecular\u2010weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"issue":"suppl 6","key":"10.1002\/rth2.12744_bb0255","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines","volume":"22","author":"Mandal\u00e0","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1002\/rth2.12744_bb0260","unstructured":"NCCN guidelines for cancer\u2010associated venous thromboembolic disease. V1.2021 Available at https:\/\/www.google.com\/search?q=NCCN+Guidelines+for+Cancer\u2010Associated+Venous+Thromboembolic+Diseas&rlz=1C1CHBF_itIT879IT879&ei=0lVdYaK_GbDnsAeOlKLYBQ&ved=0ahUKEwii8Kf2prXzAhWwM\u2010wKHQ6KCFsQ4dUDCA4&uact=5&oq=NCCN+Guidelines+for+Cancer\u2010Associated+Venous+Thromboembolic+Diseas&gs_lcp=Cgdnd3Mtd2l6EAMyBAgAEBMyCAgAEBYQHhATMggIABAWEB4QEzIICAAQFhAeEBNKBAhBGABQsuQOWLLkDmCw6w5oAXACeACAAeABiAHgAZIBAzItMZgBAKABAaABArABAMABAQ&sclient=gws\u2010wiz"},{"issue":"suppl 1","key":"10.1002\/rth2.12744_bb0265","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.thromres.2018.01.002","article-title":"Overview of VTE treatment in cancer according to clinical guidelines","volume":"164","author":"Lee","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"10.1002\/rth2.12744_bb0270","first-page":"1172","article-title":"Global anticoagulant registry in the field \u2010 venous thromboembolism (GARFIELD\u2010VTE). Rationale and design","volume":"116","author":"Weitz","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1002\/rth2.12744_bb0275","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer\u2010associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/rth2.12744_bb0280","first-page":"26","article-title":"Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism","volume":"114","author":"den Exter","year":"2015","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1002\/rth2.12744_bb0285","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer\u2010associated venous thromboembolism: a systematic review and meta\u2010analysis","volume":"105","author":"Delluc","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/rth2.12744_bb0290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"key":"10.1002\/rth2.12744_bb0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejim.2020.05.031","article-title":"A snapshot of cancer\u2010associated thromboembolic disease in 2018\u20132019: first data from the TESEO prospective registry","volume":"78","author":"Carmona\u2010Bayonas","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1002\/rth2.12744_bb0300","doi-asserted-by":"crossref","first-page":"1702431","DOI":"10.1183\/13993003.02431-2017","article-title":"Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK\u2010rearranged non\u2010small cell lung cancer","volume":"51","author":"Zugazagoitia","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1002\/rth2.12744_bb0305","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti\u2010VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1002\/rth2.12744_bb0310","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjc.6606074","article-title":"Bleeding events in bevacizumab\u2010treated cancer patients who received full\u2010dose anticoagulation and remained on study","volume":"104","author":"Leighl","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1002\/rth2.12744_bb0315","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer\u2010associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1002\/rth2.12744_bb0320","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1002\/rth2.12744_bb0325","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1002\/rth2.12744_bb0330","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/17474086.2013.842124","article-title":"Thrombosis in pediatric cancer: identifying the risk factors to improve care","volume":"6","author":"Athale","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"suppl 1","key":"10.1002\/rth2.12744_bb0335","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.thromres.2018.01.019","article-title":"Thrombosis in pediatric patients with leukemia","volume":"164","author":"Levy\u2010Mendelovich","year":"2018","journal-title":"Thromb Res"},{"issue":"3","key":"10.1002\/rth2.12744_bb0340","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.thromres.2013.12.021","article-title":"Venous thromboembolism in children with cancer \u2010 a population\u2010based cohort study","volume":"133","author":"Walker","year":"2014","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12744_bb0345","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.09.002","article-title":"Epidemiology of venous thromboembolism in hematological cancers: the Scandinavian Thrombosis and Cancer (STAC) cohort","volume":"158","author":"Gade","year":"2017","journal-title":"Thromb Res"},{"issue":"11","key":"10.1002\/rth2.12744_bb0350","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1160\/TH17-02-0109","article-title":"Increasing incidence and recurrence rate of venous thromboembolism in paediatric oncology patients in one single centre over 25 years","volume":"117","author":"Klaassen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1002\/rth2.12744_bb0355","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.thromres.2007.12.006","article-title":"Thromboembolism in children with lymphoma","volume":"122","author":"Athale","year":"2008","journal-title":"Thromb Res"},{"issue":"24","key":"10.1002\/rth2.12744_bb0360","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1002\/rth2.12744_bb0365","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence\u2010based clinical practice guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"12","key":"10.1002\/rth2.12744_bb0370","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/jth.14613","article-title":"Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta\u2010analysis","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1002\/rth2.12744_bb0375","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX\u2010ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric Acute Lymphoblastic Leukaemia (ALL)\u2010rationale and design","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1002\/rth2.12744_bb0380","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open\u2010label, phase 2b\/3, non\u2010inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1002\/rth2.12744_bb0385","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792200142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792200142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:23:56Z","timestamp":1762863836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792200142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S247503792200142X"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12744","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment\u2014A report from ICTHIC 2021","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12744"}}